Advisors lead their fields in patent law,
nutraceuticals & ethnobotany
VANCOUVER, BC, Feb. 1, 2022 /CNW/ - Numinus Wellness Inc.
("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a
mental healthcare company advancing innovative treatments and safe,
evidence-based psychedelic-assisted therapies, is pleased to
announce the appointment of three key advisors to its new
Bioscience Advisory Board.
"We are delighted to welcome these experts to our advisory
team," said Sharan Sidhu, Numinus'
Science Officer and General Manager. "These appointments point to
the rigour of the research and development that Numinus has already
completed and indicate the compelling IP strategy and milestones we
anticipate in 2022 and beyond. We look forward to gathering
strategic insights from our advisors to help us advance our project
pipeline."
The following advisors have been appointed:
Graham Pechenik (JD) – Patent
Attorney & Founder, Calyx Law
Mr. Pechenik is a registered patent attorney and the founder of
Calyx Law, an industry-leading law firm specialized in IP relating
to cannabis and psychedelics. Mr. Pechenik has a BS from UC San
Diego, choosing Cognitive Neuroscience and Biochemistry majors
after his first psychedelic experiences inspired deep curiosity
about the bases for changes in consciousness; and a JD from
New York University, where he initially
pursued interests in bioethics and cognitive liberty. After a
decade obtaining and defending patents for Fortune 500 companies
across the agricultural, chemical, pharmaceutical, biotech, and
technology industries, including working on several landmark patent
cases both at trial and on appeal, Mr. Pechenik started Calyx Law
to help cannabis and psychedelics ventures design and implement
their IP strategies. Mr. Pechenik also contributes to Psilocybin
Alpha as editor-at-large, writing about psychedelics IP and
contributing to psychedelics patent, legalization, and
decriminalization trackers, and is a member of Chacruna's Council
for the Protection of Sacred Plants.
Dr. Paul Spagnuolo (PhD) –
Associate Professor, University of
Guelph
Dr. Spagnuolo is an associate professor at the University of Guelph and past assistant professor
at the University of Waterloo,
specialized and award-winning in the development of nutraceuticals
as novel therapeutics using cellular biology. He is a past member
of the Natural Health Products Research Society of Canada and has received funding from the
Canadian Institutes of Health Research (CIHR) and the Natural
Sciences and Engineering Research Council of Canada (NSERC). Dr. Spagnuolo's research
focuses on understanding the therapeutic potential of
nutraceuticals (i.e. foods that provide medical or health benefits)
and has included investigation of anti-cancer effects in certain
compounds. He is experienced in developing novel, multidisciplinary
techniques that combine drug discovery platforms traditionally used
in the pharmaceutical industry with new areas of study.
Dr. Cory Harris (PhD) –
Associate Professor, University of
Ottawa
Dr. Harris is an associate professor at the University of Ottawa, specialized in the
ethnobotany, chemistry and bioactivity of plants. His work involves
collaboration with Inuit and First Nations communities, and
projects have included investigating the ethical and evidence-based
use of alternative medicines and the health benefits and risks of
wild plant foods. Dr. Harris also heads a graduate research
community that undertakes special interest projects, operating out
of UOttawa and supported by NSERC, Mitacs and the Province of
Ontario.
"As Numinus Bioscience continues to demonstrate leadership in
developing novel products and processes, we see an opportunity to
invite expert advisors to help us discover new areas for
collaboration and innovation," said Payton
Nyquvest, Numinus' Founder and CEO. "These appointments
reflect our multidisciplinary thinking and intent to focus on
natural products as a major component of our IP strategy, in
addition to investigating defensible patent opportunities that
support both long-term commercial scaling and safe and equitable
access for the public."
The new Bioscience Advisory Board will contribute strategically
to advancing Numinus' IP strategy, including product development
and clinical trial activities out of the Company's Health
Canada-licensed research facility, Numinus Bioscience. It joins
Numinus' existing General and Clinical advisory boards, comprised
of leading industry and subject-matter experts who have been
selected to support corporate and therapeutic protocol development.
Among them are Drs. Gabor Maté, Dennis
McKenna and Zachary
Walsh.
About Numinus
Numinus Wellness helps people to heal and be well through the
development and delivery of innovative mental health care and
access to safe, evidence-based psychedelic-assisted therapies. The
Numinus model – including psychedelic production, research, and
clinic care – is at the forefront of a transformation aimed at
healing rather than managing symptoms for depression, anxiety,
trauma, pain and substance use. At Numinus, we are leading the
integration of psychedelic-assisted therapies into mainstream
clinical practice and building the foundation for a healthier
society.
Learn more at numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
Forward-Looking Statements
Statements and other
information contained in this press release about anticipated
future events constitute forward-looking statements.
Forward-looking statements are often, but not always, identified by
the use of words such as "seek", "anticipate", "believe", "plan",
"estimate", "expect" and "intend" and statements that an event
"may", "will", "should", "could" or "might" occur or other similar
expressions. Forward-looking statements are subject to risks and
uncertainties and other factors that could cause actual results to
differ materially from those contained in the forward-looking
statements. Forward-looking statements are based on estimates and
opinions of management at the date the statements are made. The
Company does not undertake any obligation to update forward-looking
statements even if circumstances or management's estimates or
opinions should change except as required by applicable laws.
Investors should not place undue reliance on forward-looking
statements.
View original
content:https://www.prnewswire.com/news-releases/numinus-appoints-new-bioscience-advisors-to-advance-ip-development-301472197.html
SOURCE Numinus Wellness Inc.
